Komori
Other Disclosures4890Tsubota Laboratory IncorporatedPharmaceuticals

ROHTO PHARMACEUTICAL CO.,LTD. launches TLM-018-related product

ROHTO PHARMACEUTICAL CO.,LTD. launched Rohto Eye Vision, a TLM-018-related product it had been developing based on research findings from 坪田ラボ, on 26 March 2026. The product is eye drops intended to address eye fatigue in children caused by the use of digital devices.

Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

TLM-018-related productRohto Eye Vision
Applicable field (uses covered by this announcement)

Self-care for eye fatigue in children and measures to address digital stress caused by the use of digital devices

Launch date26 March 2026 (already launched)
Relationship between the counterparty and the company
Tsubota Laboratory Incorporated4890
Relationship with the Company

Relationship concerning a product whose development has been promoted by ROHTO PHARMACEUTICAL CO.,LTD. based on the Company's research findings. No capital or personnel relationship is stated.

CounterpartyROHTO PHARMACEUTICAL CO.,LTD.
Impact on Business Performance

The impact on results for the current fiscal year is expected to be minor. Over the medium to long term, the product is expected to contribute to strengthening the business foundation.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Announcement by ROHTO PHARMACEUTICAL CO.,LTD. (https://www.rohto.co.jp/news/release/2026/0326_01/)

Announced details
ItemDetails
Names of Products / Services CoveredTLM-018-related product, Rohto Eye Vision
CounterpartyROHTO PHARMACEUTICAL CO.,LTD.
Relationship with the CompanyRelationship concerning a product whose development has been promoted by ROHTO PHARMACEUTICAL CO.,LTD. based on the Company's research findings. No capital or personnel relationship is stated.
Launch date26 March 2026 (already launched)
Applicable areaSelf-care for eye fatigue in children and measures to address digital stress caused by the use of digital devices
Impact on Business PerformanceThe impact on results for the current fiscal year is expected to be minor. Over the medium to long term, the product is expected to contribute to strengthening the business foundation.
SourceAnnouncement by ROHTO PHARMACEUTICAL CO.,LTD. (https://www.rohto.co.jp/news/release/2026/0326_01/)
Items this document does not state (11)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To address the social issue of the burden on children's eyes and the impact on visual function caused by prolonged use of smartphones, tablets and other devices, and to put research findings related to maintaining and improving visual function and eye health into practice.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
ROHTO PHARMACEUTICAL CO.,LTD. launches TLM-018-related product | Tsubota Laboratory Incorporated (4890) timely disclosure | Komori